Given these findings, our results provide a rationale for targeting MDSC function or PD-L1 in conjunction with PI3K p110γ inhibition to promote cytotoxicity and enhanced efficacy of other therapeutics such as immune checkpoint inhibitors against poorly immunogenic HNSCC [54]. Here, CD274 is linked to head and neck squamous cell carcinoma.